ACRC Inhibitors
Chemical inhibitors of ACRC can affect the protein's activity by targeting various cellular signaling pathways and enzymes that are involved in regulating its function. Allopurinol, for instance, is known to inhibit xanthine oxidase, thereby reducing the production of reactive oxygen species (ROS). Since ROS are often implicated in the activation of multiple cellular signaling pathways, their reduction can attenuate the pathways that potentially modulate ACRC activity, leading to its functional inhibition. Diphenyleneiodonium chloride similarly contributes to the inhibition of ACRC by inhibiting NADPH oxidases, again decreasing ROS levels and thus potentially limiting the oxidative stress-related modulation of ACRC. PD98059 targets the MAPK/ERK pathway, specifically inhibiting MEK, which subsequently prevents the activation of ERK – an essential step for the activation of numerous proteins. If ACRC's activity is contingent upon ERK signaling, then PD98059 would inhibit ACRC by preempting this necessary activation step.
On the other hand, SB203580 acts on the p38 MAPK pathway, known for its role in inflammatory responses and stress-induced signaling. By inhibiting p38 MAPK, SB203580 could prevent the activation of downstream targets, potentially including ACRC. LY294002 and Wortmannin, both PI3K inhibitors, disrupt the PI3K/Akt pathway, which is central to many cellular processes including growth and survival. This disruption can prevent necessary phosphorylation events or activation signals required by ACRC, resulting in its inhibition. U73122's inhibition of phospholipase C can hinder the production of second messengers like diacylglycerol and inositol triphosphate, possibly inhibiting ACRC. ML-7 targets myosin light chain kinase, which could alter the actin cytoskeleton and thereby inhibit ACRC. Lastly, chelerythrine and Gö 6983, both inhibitors of protein kinase C, and KT5823, an inhibitor of protein kinase G, can inhibit ACRC by preventing the activation of these kinases, which may be required for the optimal functioning or regulation of ACRC through phosphorylation-dependent mechanisms or other regulatory processes influenced by these kinases.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol inhibits xanthine oxidase, which could decrease the production of reactive oxygen species (ROS). Since ROS can activate multiple signaling pathways that may be involved in the activity of ACRC, the reduction in ROS can lead to the functional inhibition of ACRC by attenuating these signaling pathways. | ||||||
Diphenyleneiodonium chloride | 4673-26-1 | sc-202584E sc-202584 sc-202584D sc-202584A sc-202584B sc-202584C | 10 mg 25 mg 50 mg 100 mg 250 mg 500 mg | $151.00 $136.00 $317.00 $405.00 $944.00 $1837.00 | 24 | |
This compound inhibits NADPH oxidases, which are a source of reactive oxygen species. By inhibiting ROS production, it can inhibit signaling pathways that rely on oxidative stress, thereby potentially inhibiting ACRC if its function is modulated by such pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK/ERK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK, which might be necessary for the full activation or stabilization of ACRC, thereby leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If ACRC activity is regulated by the p38 MAPK signaling pathway, inhibition of p38 MAPK by SB203580 could lead to decreased activation of ACRC, resulting in its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K/Akt pathway can regulate various proteins and cellular processes. Inhibition of PI3K by LY294002 could disrupt signaling required for ACRC function, resulting in its inhibition. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). If ACRC function depends on the actin cytoskeleton regulated by MLCK, inhibition of MLCK by ML-7 could lead to changes in cytoskeletal dynamics, resulting in the inhibition of ACRC. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, it can disrupt the PI3K/Akt pathway, which could be essential for ACRC function. Thus, wortmannin can lead to functional inhibition of ACRC by disrupting its activation or stabilization through this pathway. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is an inhibitor of protein kinase C (PKC). If ACRC activity is modulated by PKC-dependent signaling, inhibition of PKC by chelerythrine could result in the reduction of ACRC activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a broad-spectrum PKC inhibitor. Similar to chelerythrine, if ACRC is regulated by PKC signaling, Gö 6983 could inhibit this pathway, leading to the functional inhibition of ACRC. | ||||||
KT5823 | 126643-37-6 | sc-3534 sc-3534A sc-3534B | 100 µg 1 mg 5 mg | $182.00 $1228.00 $4895.00 | 21 | |
KT5823 is a selective inhibitor of protein kinase G (PKG). If PKG signaling is involved in the regulation of ACRC, then inhibition of PKG by KT5823 could lead to the functional inhibition of ACRC by disrupting necessary phosphorylation events or other regulatory mechanisms influenced by PKG. | ||||||